Details:

Alternative Title:
Influenza Other Respir Viruses
Personal Author:
Dharan, Nila J. ; Fry, Alicia M. ; Kieke, Burney A. ; Coleman, Laura ; Meece, Jennifer ; ... More +
Dharan, Nila J. ; Fry, Alicia M. ; Kieke, Burney A. ; Coleman, Laura ; Meece, Jennifer ; Vandermause, Mary ; Gubareva, Larisa V. ; Klimov, Alexander I. ; Belongia, Edward A. Less -
Description:
Nineteen patients with oseltamivir-resistant seasonal influenza A (H1N1) infections were randomized to receive oseltamivir or placebo. Nasopharyngeal swabs were obtained, and clinical and virologic outcomes were compared, stratified by early or late treatment. Neuraminidase inhibition assay and pyrosequencing for H275Y confirmed resistance. Twelve (63%) patients received oseltamivir; 8 (67%) received late treatment. Seven (37%) patients received placebo; 6 (86%) presented >48 hours after onset. Time to 50% decrease in symptom severity, complete symptom resolution, and first negative culture were shortest among the early treatment group. While sample size prohibits a strong conclusion, future studies should evaluate for similar trends.
Subject:
[+]
Adolescent
Adult
Antiviral
Antiviral Agents
Child
Child, Preschool
Drug Resistance, Viral
Female
Humans
Influenza
Influenza, Human
Influenza A Virus, H1N1 Subtype
Male
Middle Aged
Oseltamivir
Oseltamivir Effectiveness
Part 1
Resistance
Seasons
Short Article
Young Adult

Source:
Influenza Other Respir Viruses. 6(3):153-158
Pubmed ID:
22118629
Pubmed Central ID:
PMC4941666
Document Type:
Journal Article
Collection(s):
CDC Public Access
Main Document Checksum:
[+]
urn:sha256:3677dba0c508960605c8a78f756f6b864783f83fc76d36757a94b4f70080c480
File Type:

Supporting Files

• 	IRV-6-153-g001.gif	gif
  	IRV-6-153-g001.jpg	jpeg
  	IRV-6-153-g002.gif	gif
  	IRV-6-153-g002.jpg	jpeg
  	IRV-6-153.nxml	xml

More +